New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone 4mg; methylprednisolone 4mg - tablet - 4 mg - active: methylprednisolone 4mg excipient: calcium stearate lactose monohydrate liquid paraffin purified water sucrose active: methylprednisolone 4mg excipient: calcium stearate lactose monohydrate maize starch purified water sucrose - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). · congenital adrenal hyperplasia. · nonsuppurative thyroiditis · hypercalcemia associated with cancer

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - hydrocortisone sodium succinate 133.7mg equivalent to 100 mg hydrocortisone - powder for injection - 100 mg - active: hydrocortisone sodium succinate 133.7mg equivalent to 100 mg hydrocortisone excipient: dibasic sodium phosphate monobasic sodium phosphate sodium hydroxide benzyl alcohol water for injection water for injection - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids when applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively and in the event of severe trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 1 g (formed in process from methylprednisolone hemisuccinate and sodium hydroxide) - powder for injection - 1 g - active: methylprednisolone sodium succinate 1 g (formed in process from methylprednisolone hemisuccinate and sodium hydroxide) excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcaemia associated with cancer

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 2 g - powder for injection - 2 g - active: methylprednisolone sodium succinate 2 g - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcaemia associated with cancer

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 728.67mg equivalent to 575 mg of free base (575 mg/4.6ml = 500 mg/4ml). - injection with diluent - 500 mg/4ml - active: methylprednisolone sodium succinate 728.67mg equivalent to 575 mg of free base (575 mg/4.6ml = 500 mg/4ml). excipient: dibasic sodium phosphate monobasic sodium phosphate sodium hydroxide water for injection benzyl alcohol water for injection water for injection - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcaemia associated with cancer

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 62.5 mg/ml - powder for injection - 125 mg/2ml - active: methylprednisolone sodium succinate 62.5 mg/ml excipient: dibasic sodium phosphate monobasic sodium phosphate sodium hydroxide benzyl alcohol water for injection water for injection - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcaemia associated with cancer

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 40 mg/ml - powder for injection - 40 mg/ml - active: methylprednisolone sodium succinate 40 mg/ml excipient: dibasic sodium phosphate lactose monobasic sodium phosphate sodium hydroxide benzyl alcohol water for injection water for injection - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used). preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcaemia associated with cancer

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - hydrocortisone 1%{relative} - topical cream - 1% w/w - active: hydrocortisone 1%{relative} excipient: cetomacrogol 1000 cetostearyl alcohol chlorocresol liquid paraffin purified water white soft paraffin - for topical application for the temporary relief of symptoms associated with acute and chronic corticosteroid responsive conditions including, minor skin irritations, itching and rashes due to eczema, dermatitis, contact dermatitis (such as rashes due to cosmetics and jewellery), psoriasis, anogenital pruritus and sunburn.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - neomycin as the sulfate - oral powder, pre-mix - neomycin as the sulfate antibiotic active 1000.0 g/kg - nutrition & metabolism - cattle | pigs | poultry | beef | boar | bos indicus | bos taurus | bovine | breeders | broiler | buffalo | bull | bullock | calf - bacterial enteritis | escherichia coli (e. coli) | proteus spp. | pseudomonas spp. | salmonella | including b-lactamase producin | post-weaning bacterial enterit | salmonellosis

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - hydrocortisone acetate 10.5%{relative} (includes 5 % excess) - foam - 10% w/w - active: hydrocortisone acetate 10.5%{relative} (includes 5 % excess) excipient: cetyl alcohol emulsifying wax methyl hydroxybenzoate polyoxyethylene stearyl ether propyl hydroxybenzoate propylene glycol purified water trolamine - colifoam rectal foam is indicated for topical treatment of inflammation occurring in the rectal mucosa, e.g. ulcerative colitis, proctosigmoiditis and granular proctitis.